FNCH Stock - Finch Therapeutics Group, Inc.
Unlock GoAI Insights for FNCH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $107,000 | $861,000 | $18.53M | $7.72M |
| Gross Profit | $-174,000 | $-1,413,000 | $-4,646,000 | $-38,747,000 | $-25,425,000 |
| Gross Margin | N/A | -1320.6% | -539.6% | -209.1% | -329.4% |
| Operating Income | $-18,859,000 | $-34,002,000 | $-95,120,000 | $-59,985,000 | $-39,436,000 |
| Net Income | $-13,877,000 | $-74,754,000 | $-114,646,000 | $-58,160,000 | $-39,248,000 |
| Net Margin | N/A | -69863.6% | -13315.4% | -313.8% | -508.5% |
| EPS | $-8.64 | $-46.59 | $-72.12 | $-36.72 | $-24.39 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 9th 2022 | H.C. Wainwright | Initiation | Buy | $17 |
Earnings History & Surprises
FNCHEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 13, 2024 | — | $-3.01 | — | — |
Q2 2024 | May 10, 2024 | — | $-2.41 | — | — |
Q1 2024 | Mar 25, 2024 | — | $-1.89 | — | — |
Q4 2023 | Nov 8, 2023 | — | $-1.51 | — | — |
Q3 2023 | Aug 10, 2023 | $-4.51 | $-4.33 | +4.0% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-2.70 | $-15.62 | -478.5% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-16.48 | — | — |
Q4 2022 | Nov 10, 2022 | $-12.01 | $-13.51 | -12.5% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-13.81 | $-14.41 | -4.3% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.32 | $-15.62 | -4781.2% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-12.04 | — | — |
Q4 2021 | Nov 10, 2021 | $-12.61 | $-6.31 | +50.0% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-8.41 | $-9.61 | -14.3% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.24 | $-1.00 | -316.7% | ✗ MISS |
Q1 2021 | Jan 9, 2021 | — | $-46.85 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-36.65 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-30.71 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-30.13 | — | — |
Latest News
Frequently Asked Questions about FNCH
What is FNCH's current stock price?
What is the analyst price target for FNCH?
What sector is Finch Therapeutics Group, Inc. in?
What is FNCH's market cap?
Does FNCH pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to FNCH for comparison